PDE5A and pulmonary arterial hypertension: PDE5 inhibitors have been proposed to act mainly as pulmonary vasodilators since they reduce pulmonary pressure in patients with PAH, and lack of significant systemic vasodilation [25], but our results suggest that they are able to induce a similar vasodilation in PA and MA.